Back to Search
Start Over
Efficacy and safety of Ginkgo biloba extract as an “add-on” treatment to metformin for patients with metabolic syndrome: a pilot clinical study
- Source :
- Therapeutics and Clinical Risk Management. 14:1219-1226
- Publication Year :
- 2018
- Publisher :
- Informa UK Limited, 2018.
-
Abstract
- Background and aim Ginkgo biloba (GKB) extract has shown to be beneficial in experimental models of metabolic and inflammatory disorders such as diabetes and metabolic syndrome (MTS). The objective of this pilot clinical study was to evaluate the effects of GKB extract as an "add-on" treatment with metformin (Met) in MTS patients. Patients and methods We performed a randomized, placebo-controlled, double-blinded clinical study in subjects with MTS. Forty patients completed the 90-day clinical trial and were randomly allocated to administer either GKB extract (120 mg capsule/day) or placebo (120 mg starch/day) as an add-on treatment with their currently used doses of Met for 90 days. During the study, body mass index (BMI), waist circumference (WC), serum leptin, glycated hemoglobin (HbA1c), fasting serum glucose (FSG), insulin, insulin resistance (IR), visceral adiposity index (VAI), lipid profile, and the inflammatory markers high sensitive C-reactive protein (hsCRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were evaluated. Results GKB extract significantly decreases HbA1c, FSG and insulin levels, IR, BMI, WC, VAI, serum leptin, and the inflammatory markers compared to baseline values. Simultaneously, GKB did not negatively affect the functions of the liver, kidney, and hematopoietic system. Conclusion The use of GKB extract as an adjuvant with Met was effective in improving the outcome of patients with MTS.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
medicine.medical_treatment
Placebo
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Insulin resistance
Internal medicine
Diabetes mellitus
medicine
Pharmacology (medical)
General Pharmacology, Toxicology and Pharmaceutics
Chemical Health and Safety
medicine.diagnostic_test
business.industry
Insulin
General Medicine
medicine.disease
Metformin
030104 developmental biology
chemistry
030221 ophthalmology & optometry
Glycated hemoglobin
Metabolic syndrome
Lipid profile
business
Safety Research
medicine.drug
Subjects
Details
- ISSN :
- 1178203X
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Therapeutics and Clinical Risk Management
- Accession number :
- edsair.doi...........253d203610b394a329fef0edcf1eb8d6